Sai Parenterals Q4FY26 & FY26 Results: Revenue at ₹198 Cr & ₹381 Cr
Sai Parenterals reported Q4 FY26 consolidated revenue of ₹198 crore and FY26 consolidated revenue of ₹381 crore. Standalone FY26 revenue grew 31% to ₹162 crore, with EBITDA up 23% to ₹33 crore and PAT up 64% to ₹17 crore. CDMO revenue surged over 250% YoY. The company aims to expand its global injectable formulations market and capitalize on CDMO opportunities.
The announcement details strong financial performance and strategic growth initiatives, which are material for investors. The information provides a clear picture of the company's current standing and future direction.
The company reported strong year-on-year growth in standalone revenue, EBITDA, and PAT. The CDMO business also showed significant growth, and future expansion plans indicate a positive outlook.
Sai Parenterals Limited (SAIPARENT) has announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported consolidated revenue of ₹198 crore for Q4 FY26 and ₹381 crore for the full year FY26. The EBITDA for Q4 FY26 stood at ₹29 crore.
Standalone FY26 performance showed significant growth, with revenue increasing by 31% YoY to ₹162 crore, and EBITDA growing by 23% YoY to ₹33 crore. Profit After Tax (PAT) for standalone FY26 surged by 64% YoY to ₹17 crore, with a PAT margin of 10%.
The company's CDMO (Contract Development and Manufacturing Organization) business demonstrated robust growth, with revenue surging over 250% year-on-year. This growth is attributed to deeper engagement with customers and the successful consolidation of Noumed Pharmaceuticals Pty Limited.
Operational highlights include the expansion of the product portfolio by 93 dossiers in FY26, with 88 filings for regulated/emerging markets and 5 TGA Australia dossiers through Noumed. The company has 67 dossiers under development, providing visibility for export-led growth in FY27. Sai Parenterals has also secured long-term CDMO contracts and enhanced its global market access through expansion in Australia and New Zealand.
The consolidated financials include wholly owned subsidiaries Revat Laboratories Private Limited and Sai Parenterals Pte. Ltd. (Singapore), and a 74.6% stake in Noumed Pharmaceuticals Pty Limited (Australia). The acquisition of Noumed was completed on November 12, 2025, and its financials have been consolidated from that date.
Future plans include capacity expansion and upgradation of manufacturing facilities, establishment of a new R&D Centre, and strengthening presence in regulated markets with an upcoming manufacturing facility in Adelaide, Australia. The company also plans to focus on new product development and grow its Branded Generic Formulations business.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.